Latest Us Market News

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

Genetic Signatures reported steady quarterly sales of $4.4 million, reflecting seasonal demand in Australia, while restructuring its US operations to accelerate growth. A new US contract and strategic partnerships signal potential for future expansion.

BetMakers Technology Group delivered a standout Q4 FY25 with record adjusted EBITDA and improved margins, while announcing a strategic acquisition to deepen its US market presence.

BetMakers Technology Group capped FY25 with its strongest quarterly results ever, showcasing record profitability, positive cash flow, and a debt-free balance sheet. The company’s strategic investments and recent capital raise set the stage for accelerated growth in FY26, including a key acquisition in Nevada.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

Amaero Ltd reports solid June quarter revenue and signs a pivotal five-year exclusive supply agreement with Velo3D, underpinning its growth outlook and updated EBITDA guidance for FY2027.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Pacific Edge Limited has opened a $5 million Share Purchase Plan at $0.10 per share, conditional on shareholder approval of a prior $16.1 million Placement. The capital raise aims to extend the company’s cash runway and accelerate US market adoption of its bladder cancer diagnostic tests amid Medicare non-coverage.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Phoslock Environmental Technologies reported a $474,000 cashflow deficit in Q2 2025, with sales impacted by deferred European projects and ongoing US tariff uncertainties. Factory refurbishment delays push production restart to early 2026.